Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock

Bluejay Diagnostics (NASDAQ:BJDX) announced baseline clinical data from its SYMON-II study, evaluating IL-6 as a biomarker for 28-day mortality risk in sepsis patients. The study included 777 patients, with an 18% mortality rate. The company aims to use this data to support a regulatory submission for its Symphony IL-6 Test, which is not yet FDA-approved.

Original reporting
Published Oct 6, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 11:26 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$BJDX
Neutral
medium confidence
Mentioned
$BJDX
Relevance
8/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$BJDXNeutralMed
01

Why it matters

The SYMON‑II dataset provides a larger, diverse patient cohort, a key step toward a 510(k) submission.

02

Market read

First public release of pivotal trial data; may influence valuation ahead of regulatory filing.

03

What to watch

Potential competition from larger diagnostic firms and uncertainty around FDA review timeline.

Relevance 8/10Novelty 8/10Timing: today

Background

Bluejay Diagnostics is a Nasdaq‑listed company developing a rapid IL‑6 test for sepsis risk assessment.

Company-level read

Ticker impact

$BJDXNeutralMedium confidence
Context

Bluejay Diagnostics released baseline characteristics of its SYMON-II pivotal clinical validation study, the first public disclosure of these data.

Expected impact

potential upside as investors price in progress toward FDA clearance, but limited until performance data are fully analyzed.

Evidence & confidence

Clinical data are material for a diagnostic company, yet the study does not yet prove test performance; price reaction may be modest.

Market effects

May boost sentiment for sepsis diagnostics and broader point-of-care biomarker market.

Limited to U.S. biotech and diagnostic sectors.

Low; relevance confined to healthcare investors.

Counterpoint

Data may not translate into regulatory approval; investors could be over‑optimistic.

Key entities

  • Bluejay Diagnostics, Inc.

    Developer of the Symphony Suite IL‑6 test.

Related articles

$BJDXMed

Bluejay Diagnostics Reports Third Quarter 2026 Financial Results and Provides Business Update

Bluejay Diagnostics, Inc. (BJDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bluejay Diagnostics Reports Third Quarter 2026 Financial Results and Provides Business Update Completes SYMON-II clinical study enrollment and advances clinical validation activities Achieves critical manufacturing milestone ahead of contractual deadline, strengtheni

$BJDXMedAI 8/10

Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock

Bluejay Diagnostics, Inc. (BJDX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 For Immediate Release Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock. SYMON-II Clinical Validation Dataset Represents a Key Milestone as Bluejay Advances the Symphony™ IL-6 Test Towar